Vanda Pharmaceuticals (STU:VM4) Ending Cash Position : €98.2 Mil (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Ending Cash Position?

Vanda Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2024 was €98.2 Mil.

Vanda Pharmaceuticals's quarterly Ending Cash Position declined from Jun. 2024 (€96.1 Mil) to Sep. 2024 (€91.0 Mil) but then increased from Sep. 2024 (€91.0 Mil) to Dec. 2024 (€98.2 Mil).

Vanda Pharmaceuticals's annual Ending Cash Position declined from Dec. 2022 (€127.9 Mil) to Dec. 2023 (€125.0 Mil) and declined from Dec. 2023 (€125.0 Mil) to Dec. 2024 (€98.2 Mil).

Vanda Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Vanda Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Ending Cash Position Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

50.65

46.54

127.91

124.98

98.16

Vanda Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															124.98	115.58	96.08	90.97	98.16

Vanda Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vanda Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	130.158	+	-31.998
	=	98.2

Vanda Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	96.275	+	1.885
	=	98.2

Vanda Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

VNDA:USA 0LKB:UK VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals Headlines

No Headlines